

Public Dashboard

Reporting Period: January 2022- December 2022 (Current Period); January 2021 – December 2021 (Prior Period)

Includes all covered plan participants (Active, Non-Medicare Retirees and Medicare Retirees) unless otherwise noted




Table of Contents

- Page 3 Enrollment (Actives)
- Page 4 Enrollment (Retirees)
- Page 5 Plan Paid By Setting
- Page 9 Plan Paid By Age Band and Gender
- Page 13 Emergency Room Visits
- Page 17 Top 15 Drugs
- Page 21 Top 15 Prescription Drug Disease Indications
- Page 25 Top 15 Diagnosis Categories for Medical Claims
- Page 29 Distribution of Claims By Membership



Enrollment: Actives *January* 2022 – *December* 2022

Average Employee and Dependent Counts



Average Employee and Dependent Counts

Line of Business	Employee Count	Dependent Count	Total Count	PEPM ¹
Partnership	28,525	37,043	65,568	\$1,425.24
State	46,958	66,340	113,298	\$1,527.16
Total	75,484	103,383	178,866	\$1,488.64




¹ Per Employee Per Month

² Partnership is higher due to membership located in counties that have a higher average cost of care, Regional pricing adjustments account for this disparity.

Enrollment: Retirees *January* 2022 – *December* 2022

Average Retiree and Dependent Counts



Average Retiree and Dependent Counts


Status	Retiree Count	Dependent Count	Total Count	PEPM ¹
Non-Medicare Retirees	18,362	17,381	35,743	\$1,606
Medicare Retirees	38,822	18,440	57,261	\$1,476



Plan Paid By Setting – State Plan Active Population

January 2022 – December 2022(Current Period); January 2021 – December Current vs Prior

2021 (Prior Period)






Plan Paid By Setting – State Plan Non-Medicare Retirees

January 2022 – December 2022(Current Period); January 2021 – December 2021 (Prior

Period)






Plan Paid By Setting – State Plan Medicare Retirees

January 2022 – December 2022(Current Period); January 2021 – December Current vs Prior

2021 (Prior Period)






Plan Paid By Setting — Partnership Plan (includes retirees)


January 2022 – December 2022(Current Period); January 2021 – December Current vs Prior

2021 (Prior Period)






Plan Paid By Age and Gender – State Plan Active Population *January* 2022 – *December* 2022







Plan Paid By Age and Gender – State Plan Non-Medicare *January* 2022 – *December* 2022



Plan Paid By Age and Gender – State Plan Medicare Retirees *January* 2022 – *December* 2022




Plan Paid By Setting — Partnership Plan (includes retirees) *January* 2022 — *December* 2022






Emergency Room Visits - State Plan Active Population January 2022 – December 2022(Current Period); January 2021 – December 2021 (Prior Period)

ER Visits Per Month



State Fiscal Year	Total ER Visits	Visits per 1,000 Covered Lives
Current	31,293	271
Prior	29,879	251







Emergency Room Visits - State Plan Non-Medicare Retirees

January 2022 – December 2022(Current Period); January 2021 – December 2021 (Prior Period)

ER Visits Per Month



State Fiscal Year	Total ER Visits	Visits per 1,000 Covered Lives
Current	12,088	359
Prior	11,191	338






Emergency Room Visits - State Plan Medicare Retirees

January 2022 – December 2022(Current Period); January 2021 – December 2021 (Prior Period)

ER Visits Per Month



State Fiscal Year	Total ER Visits	Visits per 1,000 Covered Lives
Current	29,091	519
Prior	25,389	464







Emergency Room Visits - Partnership Plan (includes retirees)

January 2022 – December 2022(Current Period); January 2021 – December 2021 (Prior Period)

ER Visits Per Month



State Fiscal Year	Total ER Visits	Visits per 1,000 Covered Lives
Current	15,927	235
Prior	14,395	231





Top 15 Drugs – State Plan Active Population January 2022 – December 2022 By Plan Paid

Rank	Drug	Disease Indication	Total Plan Paid	Script Count	Cost Per Script
1	HUMIRA PEN	Autoimmune Disease	\$9,902,031	2,150	\$4,606
2	OZEMPIC	Diabetes	\$6,185,013	10,439	\$592
3	STELARA	Psoriasis	\$6,118,765	675	\$9,065
4	DUPIXENT	Skin Disorders	\$6,023,338	2,355	\$2,558
5	SKYRIZI	Psoriasis	\$4,367,920	399	\$10,947
6	TRIKAFTA	Cystic Fibrosis	\$3,518,265	173	\$20,337
7	VYVANSE	ADHD/Narcolepsy	\$2,990,179	9,652	\$310
8	EXONDYS 51	M.S./Neuromuscular Disorders	\$2,371,962	52	\$45,615
9	XOLAIR	Asthma/COPD	\$2,158,609	1,094	\$1,973
10	TRULICITY	Diabetes	\$2,035,801	3,454	\$589
11	REVLIMID	Oncology	\$1,982,928	138	\$14,369
12	BIKTARVY	Viral Infections/HIV AIDS	\$1,780,040	598	\$2,977
13	COSENTYX SENSOREADY PEN	Psoriasis	\$1,765,695	686	\$2,574
14	NURTEC	Migraine	\$1,469,855	2,099	\$700
15	LATUDA	Mental Health/Neurorological Disorders	\$1,435,759	850	\$1,689

Top 15 Drugs – State Plan Non-Medicare Retirees January 2022 – December 2022 By Plan Paid

Rank	Drug	Disease Indication	Total Plan Paid	Script Count	Cost Per Script
1	HUMIRA PEN	Autoimmune Disease	\$5,035,339	1,041	\$4,837
2	OZEMPIC	Diabetes	\$2,958,713	4,466	\$662
3	DUPIXENT	Skin Disorders	\$2,277,592	873	\$2,609
4	STELARA	Psoriasis	\$2,119,671	188	\$11,275
5	SKYRIZI	Psoriasis	\$1,872,918	164	\$11,420
6	REVLIMID	Oncology	\$1,538,503	101	\$15,233
7	TRULICITY	Diabetes	\$1,412,583	2,127	\$664
8	XOLAIR	Asthma/COPD	\$1,140,860	437	\$2,611
9	TRIKAFTA	Cystic Fibrosis	\$1,053,681	48	\$21,952
10	ENBREL SURECLICK	Autoimmune Disease	\$1,008,713	363	\$2,779
11	BIKTARVY	Viral Infections/HIV AIDS	\$922,507	291	\$3,170
12	VYVANSE	ADHD/Narcolepsy	\$921,330	2,843	\$324
13	IBRANCE	Oncology	\$826,119	74	\$11,164
14	ELIQUIS	Blood Disorders	\$825,174	1,316	\$627
15	XARELTO	Blood Disorders	\$819,417	2,038	\$402

Top 15 Drugs – State Plan Medicare Retirees January 2022 – December 2022 2022 By Plan Paid

Rank	Drug	Disease Indication	Total Plan Paid	Script Count	Cost Per Script
1	ELIQUIS	Blood Disorders	\$17,964,920	23,128	\$777
2	REVLIMID	Oncology	\$12,708,944	726	\$17,505
3	HUMIRA PEN	Autoimmune Disease	\$10,203,568	1,027	\$9,935
4	XARELTO	Blood Disorders	\$7,307,565	8,317	\$879
5	IMBRUVICA	Oncology	\$7,229,079	436	\$16,580
6	VYNDAMAX	Cardiovascular/Heart Disease	\$6,956,291	190	\$36,612
7	OZEMPIC	Diabetes	\$6,556,270	5,739	\$1,142
8	JARDIANCE	Diabetes	\$6,199,586	6,715	\$923
9	TRULICITY	Diabetes	\$5,570,321	4,902	\$1,136
10	JANUVIA	Diabetes	\$5,442,134	5,907	\$921
11	MYRBETRIQ	Overactive Bladder/Urinary Incontinence	\$4,709,268	7,060	\$667
12	STELARA	Psoriasis	\$4,641,314	191	\$24,300
13	RESTASIS	Ophthalmology	\$4,438,045	3,778	\$1,175
14	DUPIXENT	Skin Disorders	\$4,167,762	1,199	\$3,476
15	ENBREL SURECLICK	Autoimmune Disease	\$4,079,628	409	\$9,975

Top 15 Drugs – Partnership Plan (includes retirees)

Rank	Drug	Disease Indication	Total Plan Paid	Script Count	Cost Per Script
1	HUMIRA PEN	Autoimmune Disease	\$6,144,230	1,405	\$4,373
2	DUPIXENT	Skin Disorders	\$3,259,228	1,316	\$2,477
3	OZEMPIC	Diabetes	\$3,106,431	5,345	\$581
4	STELARA	Psoriasis	\$2,729,306	294	\$9,283
5	VYVANSE	ADHD/Narcolepsy	\$1,850,427	6,392	\$289
6	SKYRIZI	Psoriasis	\$1,786,239	175	\$10,207
7	REVLIMID	Oncology	\$1,475,953	95	\$15,536
8	STRENSIQ	Rare Disorders	\$1,446,483	13	\$111,268
9	TRULICITY	Diabetes	\$1,128,685	1,884	\$599
10	OTEZLA	Autoimmune Disease	\$973,489	470	\$2,071
11	LATUDA	Mental Health/Neurorological Disorders	\$966,465	623	\$1,551
12	TRIKAFTA	Cystic Fibrosis	\$944,033	35	\$26,972
13	MENOPUR	Fertility	\$906,736	217	\$4,179
14	ENBREL SURECLICK	Autoimmune Disease	\$882,018	382	\$2,309
15	COSENTYX SENSOREADY PEN	Psoriasis	\$871,863	327	\$2,666
A a Danto a rabin	n ratiraa mambarahin inaraasaa thawwill ba	war auto di a a ra va ta li c			

Top 15 Prescription Drug Disease Indications State Plan Active Population

Rank	Disease Indication	Plan Paid	Script Count	Cost Per Script
1	Autoimmune Disease	\$20,678,091	7,347	\$2,814
2	Psoriasis	\$14,184,216	2,729	\$5,198
3	Diabetes	\$14,101,464	53,336	\$264
4	Oncology	\$13,947,825	5,765	\$2,419
5	Skin Disorders	\$10,712,212	53,801	\$199
6	Multiple Sclerosis/Neuromuscular Disorders	\$9,231,364	1,436	\$6,429
7	Asthma/COPD	\$8,046,479	64,037	\$126
8	ADHD/Narcolepsy	\$7,455,947	42,723	\$175
9	Viral Infections/HIV AIDS	\$5,743,001	2,985	\$1,924
10	Mental Health/Neurorological Disorders	\$4,613,188	13,192	\$350
11	Blood Disorders	\$4,567,858	8,871	\$515
12	Cystic Fibrosis	\$4,380,420	328	\$13,355
13	Migraine	\$4,030,361	16,904	\$238
14	Vaccines/Immunizing Agents	\$3,923,360	62,588	\$63
15	Depression	\$3,853,411	85,800	\$45

Top 15 Prescription Drug Disease Indications State Plan Non-Medicare Retirees

Rank	Disease Indication	Plan Paid	Script Count	Cost Per Script
1	Autoimmune Disease	\$10,976,638	3,641	\$3,015
2	Diabetes	\$9,450,012	31,462	\$300
3	Oncology	\$8,578,342	3,022	\$2,839
4	Psoriasis	\$5,743,507	951	\$6,039
5	Asthma/COPD	\$4,316,377	25,613	\$169
6	Skin Disorders	\$4,205,495	20,848	\$202
7	Multiple Sclerosis/Neuromuscular Disorders	\$3,731,511	725	\$5,147
8	Blood Disorders	\$2,506,700	5,746	\$436
9	ADHD/Narcolepsy	\$2,437,574	11,459	\$213
10	Lipid/Cholesterol Disorders	\$2,317,198	40,709	\$57
11	Viral Infections/HIV AIDS	\$2,235,707	1,060	\$2,109
12	Mental Health/Neurorological Disorders	\$2,166,883	6,683	\$324
13	Depression	\$2,165,737	37,183	\$58
14	Vaccines/Immunizing Agents	\$2,099,691	27,976	\$75
15	Seizure Disorder	\$1,906,154	18,081	\$105

Top 15 Prescription Drug Disease Indications State Plan Medicare Retirees

Rank	Disease Indication	Plan Paid	Script Count	Cost Per Script
1	Oncology	\$58,680,835	11,976	\$4,900
2	Diabetes	\$51,865,097	91,258	\$568
3	Blood Disorders	\$33,676,213	50,233	\$670
4	Autoimmune Disease	\$30,683,583	6,463	\$4,748
5	Asthma/COPD	\$23,633,763	69,837	\$338
6	Cardiovascular/Heart Disease	\$16,416,202	19,530	\$841
7	Psoriasis	\$14,516,324	1,494	\$9,716
8	Cardiovascular/Hypertension	\$11,531,133	311,847	\$37
9	Multiple Sclerosis/Neuromuscular Disorders	\$10,625,661	1,319	\$8,056
10	Lipid/Cholesterol Disorders	\$10,205,798	160,734	\$63
11	Vaccines/Immunizing Agents	\$9,321,321	80,821	\$115
12	Skin Disorders	\$8,893,905	39,469	\$225
13	Glaucoma	\$6,990,700	30,456	\$230
14	Overactive Bladder/Urinary Incontinence	\$6,803,836	16,352	\$416
15	Ophthalmology	\$6,749,105	12,065	\$559
				23

Top 15 Prescription Drug Disease Indications Partnership Plan (includes retirees)

Rank	Disease Indication	Plan Paid	Script Count	Cost Per Script
1	Autoimmune Disease	\$12,618,319	4,716	\$2,676
2	Oncology	\$10,144,778	3,886	\$2,611
3	Diabetes	\$7,860,154	29,618	\$265
4	Psoriasis	\$6,485,444	1,272	\$5,099
5	Skin Disorders	\$5,720,205	29,215	\$196
6	Asthma/COPD	\$3,727,858	31,251	\$119
7	ADHD/Narcolepsy	\$3,608,568	25,714	\$140
8	Rare Disorders	\$3,242,038	853	\$3,801
9	Multiple Sclerosis/Neuromuscular Disorders	\$3,209,452	743	\$4,320
10	Mental Health/Neurorological Disorders	\$2,933,457	7,586	\$387
11	Vaccines/Immunizing Agents	\$2,752,770	37,166	\$74
12	Viral Infections/HIV AIDS	\$2,614,977	1,487	\$1,759
13	Blood Disorders	\$2,398,740	6,253	\$384
14	Fertility	\$2,157,071	1,471	\$1,466
15	Depression	\$2,002,602	51,796	\$39
As Partners	hip retiree membership increases, they will be reported separately.			24

Top 15 Medical Diagnosis Categories State Plan Active Population

Rank	c Diagnosis Description	Plan Paid
1	Encounter for other aftercare and medical care ¹	\$30,592,954
2	Encounter for screening for malignant neoplasms	\$30,259,407
3	Encounter for general examination without complaint, suspected or reported diagnosis ²	\$22,461,708
4	Multiple sclerosis	\$18,415,354
5	Liveborn infants according to place of birth and type of delivery	\$14,426,672
6	Contact with and (suspected) exposure to communicable diseases	\$14,352,785
7	Dorsalgia	\$13,415,471
8	Other anxiety disorders	\$12,524,369
9	Other sepsis	\$11,197,710
10	Major depressive disorder, recurrent	\$10,351,641
11	Encounter for other special examination without complaint, suspected or reported diagnosis	\$10,082,776
12	Reaction to severe stress, and adjustment disorders	\$9,917,193
13	Other joint disorder, not elsewhere classified	\$9,538,868
14	Overweight and obesity	\$9,399,544
15	COVID-19	\$9,101,444

¹This category captures admissions for cancer treatment, including chemotherapy, immunotherapy, and radiation therapy, as well as monitoring certain drug levels for patients on long-term drug therapy.

²This category captures routine physicals, well-child visits, and other general health examinations in patients who are currently not symptomatic.



Top 15 Medical Diagnosis Categories State Plan Non-Medicare Retirees

Rank	Diagnosis Description	Plan Paid
1	Encounter for other aftercare and medical care ¹	\$19,016,074
2	Encounter for screening for malignant neoplasms	\$12,858,135
3	Osteoarthritis of knee	\$6,955,463
4	Encounter for general examination without complaint, suspected or reported diagnosis ²	\$6,344,899
5	Dorsalgia	\$6,226,065
6	Other sepsis	\$5,712,256
7	Chronic ischemic heart disease	\$5,213,265
8	Multiple sclerosis	\$4,817,852
9	Atrial fibrillation and flutter	\$4,766,230
10	Other spondylopathies	\$4,569,690
11	Other joint disorder, not elsewhere classified	\$4,291,964
12	Osteoarthritis of hip	\$4,248,572
13	Type 2 diabetes mellitus	\$3,983,438
14	COVID-19	\$3,841,195
15	Major depressive disorder, recurrent	\$3,782,159

¹This category captures admissions for cancer treatment, including chemotherapy, immunotherapy, and radiation therapy, as well as monitoring certain drug levels for patients on long-term drug therapy.

²This category captures routine physicals, well-child visits, and other general health examinations in patients who are currently not symptomatic.



Top 15 Medical Diagnosis Categories State Plan Medicare Retirees

Rank	Diagnosis Description	Plan Paid
1	Encounter for other aftercare and medical care ¹	\$34,066,092
2	Other sepsis	\$22,350,601
3	Osteoarthritis of knee	\$15,554,223
4	COVID-19	\$12,386,984
5	Type 2 diabetes mellitus	\$11,570,061
6	Atrial fibrillation and flutter	\$11,458,047
7	Chronic kidney disease (CKD)	\$10,778,435
8	Chronic ischemic heart disease	\$10,363,321
9	Other spondylopathies	\$9,565,190
10	Other retinal disorders	\$9,250,122
11	Fracture of femur	\$9,128,005
12	Age-related cataract	\$8,790,052
13	Encounter for general examination without complaint, suspected or reported diagnosis ²	\$8,655,851
14	Encounter for screening for malignant neoplasms	\$8,440,583
15	Dorsalgia	\$8,146,495

¹This category captures admissions for cancer treatment, including chemotherapy, immunotherapy, and radiation therapy, as well as monitoring certain drug levels for patients on long-term drug therapy.

²This category captures routine physicals, well-child visits, and other general health examinations in patients who are currently not symptomatic.



Top 15 Medical Diagnosis Categories Partnership Plan (includes retirees)

Rank	Diagnosis Description	Plan Paid
1	Encounter for other aftercare and medical care ¹	\$21,263,986
2	Encounter for screening for malignant neoplasms	\$19,234,957
3	Encounter for general examination without complaint, suspected or reported diagnosis ²	\$14,054,208
4	Contact with and (suspected) exposure to communicable diseases	\$8,697,663
5	Dorsalgia	\$8,196,080
6	Multiple sclerosis	\$7,615,033
7	Other anxiety disorders	\$7,358,468
8	Osteoarthritis of knee	\$7,237,621
9	Liveborn infants according to place of birth and type of delivery	\$6,721,868
10	Encounter for other special examination without complaint, suspected or reported diagnosis	\$6,532,974
11	COVID-19	\$6,263,443
12	Malignant neoplasm of breast	\$6,145,395
13	Other sepsis	\$5,917,378
14	Major depressive disorder, recurrent	\$5,776,833
15	Reaction to severe stress, and adjustment disorders	\$5,773,448


¹This category captures admissions for cancer treatment, including chemotherapy, immunotherapy, and radiation therapy, as well as monitoring certain drug levels for patients on long-term drug therapy.

²This category captures routine physicals, well-child visits, and other general health examinations in patients who are currently not symptomatic.

As Partnership retiree membership increases, they will be reported separately.




January 2022 – December 2022 By Plan Paid–State Plan Active Population






January 2022 – December 2022 By Plan Paid-State Plan Non-Medicare Population





January 2022 – December 2022 By Plan Paid–State Plan Medicare Population





January 2022 – December 2022 By Plan Paid–Partnership Plan (includes retirees)

